# Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury

> **NCT01683838** · PHASE3 · COMPLETED · sponsor: **Acorda Therapeutics** · enrollment: 204 (actual)

## Conditions studied

- Spinal Cord Injury
- Muscle Spasticity

## Interventions

- **DRUG:** Fampridine-SR
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01683838
- **Lead sponsor:** Acorda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2003-11
- **Final completion:** 2004-02
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2017-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01683838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01683838, "Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT01683838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*